Federica Vianello

List of Publications by Year
in descending order

30 papers	2,494 citations	331538 21 h-index	454834 30 g-index
30 all docs	30 docs citations	30 times ranked	2894 citing authors

#	Article	IF	Citations
1	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	3.8	775
2	Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	0.8	448
3	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
4	MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome. Thyroid, 2012, 22, 890-896.	2.4	116
5	Patient Ageâ€"Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	0.8	102
6	Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. European Journal of Endocrinology, 2011, 164, 971-976.	1.9	86
7	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	1.8	80
8	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	3.0	60
9	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
10	BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy-d-glucose uptake ability. European Journal of Endocrinology, 2010, 163, 659-663.	1.9	55
11	Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience. International Journal of Radiation Oncology Biology Physics, 2007, 68, 823-829.	0.4	48
12	BRAF^{K601E} Mutation in a Patient with a Follicular Thyroid Carcinoma. Thyroid, 2011, 21, 1393-1396.	2.4	48
13	BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clinical Chemistry and Laboratory Medicine, 2011, 49, 325-329.	1.4	48
14	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41
15	The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. Thyroid, 2018, 28, 96-103.	2.4	40
16	Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology. European Journal of Endocrinology, 2019, 181, 1-11.	1.9	39
17	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
18	Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario. Frontiers in Endocrinology, 2019, 10, 552.	1.5	33

#	Article	IF	Citations
19	Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit. Frontiers in Endocrinology, 2017, 8, 273.	1.5	31
20	High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal. Thyroid, 2014, 24, 480-487.	2.4	28
21	MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinicalâ€“pathological features and outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 651-658.	1.4	25
22	Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma. International Journal of Endocrinology, 2017, 2017, 1-9.	0.6	23
23	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Oncotarget, 2015, 6, 32104-32114.	0.8	23
24	EF24 (a Curcumin Analog) and ZSTK474 Emphasize the Effect of Cabozantinib in Medullary Thyroid Cancer. Endocrinology, 2018, 159, 2348-2360.	1.4	21
25	Follicular Thyroid Carcinoma with Metastases to the Pituitary Causing Pituitary Insufficiency. Thyroid, 2011, 21, 921-925.	2.4	16
26	BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1531-1539.	1.4	12
27	Comparison of the diagnostic accuracy of combined elastosonography and <scp>BRAF</scp> analysis vs cytology and ultrasonography for thyroid nodule suspected of malignancy. Clinical Endocrinology, 2012, 77, 608-614.	1.2	10
28	Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma . Cancer Management and Research, 2019, Volume 11, 7845-7855.	0.9	6
29	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology, 2022, 13, 834075.	1.5	5
30	The role of the size in thyroid cancer risk stratification. Scientific Reports, 2021, 11, 7303.	1.6	2